IGC

IGC Pharma Inc

• Dow Jones·08/26 10:05

  IGC Pharma Is Maintained at Buy by Ascendiant Capital

• Dow Jones·08/26 10:05

  IGC Pharma Price Target Raised to $6.00/Share From $5.50 by Ascendiant Capital

• Seeking Alpha·08/24 23:42

  Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple

• Seeking Alpha·08/17 13:27

  IGC Pharma GAAP EPS of -$0.03 misses by $0.01, revenue of $0.27M beats by $0.17M

• TipRanks·08/17 12:45

  IGC Pharma sees cash runway for 12 months from quarterly report filing date

• TipRanks·08/11 12:46

  IGC Pharma strengthens regulatory readiness of Phase 2 CALMA trial

• TipRanks·07/29 12:40

  IGC Pharma evaluates potential civil remedies following federal jury verdict

• TipRanks·07/07 13:26

  IGC Pharma CEO, principal financial officer purchase over $1.15M of stock

• Seeking Alpha·07/07 13:23

  IGC Pharma CEO, finance chief buy $1.15M of common stock

• TipRanks·07/06 20:41

  IGC Pharma Executives Convert Debt Into Equity Shares

• TipRanks·06/23 16:59

  IGC Pharma announced beta version of Agentic Harmonization Assistant

• TipRanks·06/11 12:43

  IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial

• TipRanks·06/08 21:16

  IGC Pharma Extends and Amends $12 Million Loan Facility

• Dow Jones·06/08 09:31

  IGC Pharma Is Maintained at Buy by Ascendiant Capital

• Dow Jones·06/08 09:31

  IGC Pharma Price Target Raised to $5.50/Share From $5.25 by Ascendiant Capital